Allied Minds and Bristol-Myers Squibb Advance Innovation in US Academia
Allied-Bristol Life Sciences will focus on converting university research into therapeutic candidates.
Allied Minds and Bristol-Myers Squibb Company formed Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and preclinical development of biopharmaceutical innovations from leading university research institutions across the US.
Allied-Bristol Life Sciences will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development and, ultimately, approved therapies that address serious diseases. For programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb's drug discovery research expertise and Allied Minds' financial and management experience.
"The innovations developed in US research institutions represent an important resource for scientific advancement as well as economic development and financial returns," said Chris Silva, CEO of Allied Minds.
Under the terms of the agreement, the companies have jointly formed and funded Allied-Bristol Life Sciences LLC, which will support the research and development needed to take these early-stage opportunities from initial feasibility to preclinical candidacy. Allied Minds and Bristol-Myers Squibb together will form and fund new companies to conduct feasibility and full-phase discovery programs. Once a program succeeds in identifying a pre-clinical candidate, Bristol-Myers Squibb will have the option to acquire the company from Allied-Bristol Life Sciences LLC under preagreed terms.
Source: Bristol-Myers Squibb
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
